Metsera, Inc. Files 8-K with Regulatory Updates
| Field | Detail |
|---|---|
| Company | Metsera, Inc. |
| Form Type | 8-K |
| Filed Date | Sep 29, 2025 |
| Risk Level | low |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, regulatory
TL;DR
Metsera filed an 8-K on 9/29/25 covering Reg FD, other events, and financials.
AI Summary
Metsera, Inc. filed an 8-K on September 29, 2025, to report on various events. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company is incorporated in Delaware and its principal executive offices are located at 3 World Trade Center, New York, NY.
Why It Matters
This 8-K filing provides important updates and disclosures from Metsera, Inc. to investors and the public regarding company events and financial information.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting various corporate events and disclosures, not indicating any immediate financial distress or significant negative news.
Key Numbers
- 001-42489 — Commission File Number (Identifies the company's filing with the SEC)
- 92-0931552 — IRS Employer Identification No. (Tax identification number for the company)
Key Players & Entities
- Metsera, Inc. (company) — Registrant
- September 29, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 3 World Trade Center (location) — Principal Executive Offices Street 1
- New York (location) — Principal Executive Offices City
FAQ
What specific events are being disclosed under Regulation FD?
The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in this excerpt.
What are the 'Other Events' reported by Metsera, Inc.?
The filing lists 'Other Events' as an item information category, but the specific nature of these events is not detailed in the provided text.
When was Metsera, Inc. incorporated?
Metsera, Inc. was incorporated in Delaware.
What is the address of Metsera, Inc.'s principal executive offices?
The principal executive offices are located at 3 World Trade Center, 175 Greenwich Street, New York, New York, 10007.
What is the SIC code for Metsera, Inc.?
The Standard Industrial Classification (SIC) code for Metsera, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,786 words · 7 min read · ~6 pages · Grade level 16.9 · Accepted 2025-09-29 17:16:53
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share MTSR The Nasdaq Global Se
Filing Documents
- d943312d8k.htm (8-K) — 41KB
- d943312dex991.htm (EX-99.1) — 36KB
- g943312g0929074743883.jpg (GRAPHIC) — 3KB
- 0001193125-25-223440.txt ( ) — 211KB
- mtsr-20250929.xsd (EX-101.SCH) — 3KB
- mtsr-20250929_lab.xml (EX-101.LAB) — 18KB
- mtsr-20250929_pre.xml (EX-101.PRE) — 11KB
- d943312d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated as of September 29, 2025. 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including information about, among other topics, the timelines, design and results of the Company's clinical trials and data releases; the Company's product candidate pipeline and milestone events; and potential benefits of treatment with the Company's product candidates, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the Company's limited operating history; the Company's ability to generate revenue or become profitable; the Company's failure to obtain additional capital when needed on acceptable terms or at all; raising additional capital may cause dilution to the Company's stockholders or require the Company to relinquish rights to its technologies or product candidates; the Company's risks related to the satisfaction or waiver of the conditions to closing the proposed acquisition by Pfizer Inc. ("Pfizer") (including the failure to obtain necessary regulatory approvals and failure to obtain the requisite vote by the Company stockholders) in the anticipated timeframe or at all, including the possibility that the proposed acquisition does not close; the possibility that competing offers may be made; risks related to the ability to realize the anticipated benefits of the proposed acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; disruption from the transaction making it more difficult to maintain business and operational relationships, including the Company's ability to attract and retain highly qualified manage
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. METSERA, INC. Date: September 29, 2025 By: /s/ Matthew Lang Matthew Lang Chief Legal Officer and Secretary